Investing Platform founder Adnan Tanveer reports strong deal flow at Emergence 2026, with opportunities spanning ...

School to welcome first batch of 50 students in 2028-29, with most non-locals expected to be from mainland China About 20 per cent of the 50 places in the inaugural intake of Hong Kong University of ...

Jupiter Neurosciences is a B2i Digital Featured Company. See the company’s profile at At BIO, Jupiter will discuss its FDA-cleared Phase IIa clinical program in Parkinson’s disease. In November 2025, ...

Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based ...

Small-cap stocks delivered solid gains in 2025, marking another year in which the Russell 2000 Growth Index (up 13.01%) outperformed the Russell 2000 Value Index (up 12.58%). Read more here.

Winner of the Innovation Exchange Award among 1,800 participants and 600 global drug developers; advancing toward first-in-human clinical study in spinal ...

SALIAI (Guangzhou SALIAI Stem Cell Science and Technology Co., Ltd. and Guangzhou SALIAI Biological Gene Engineering Co., Ltd ...

Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform ...